Translating Aging
- Business
- Health & Fitness · Medicine
- Science · Life Sciences
Free on the App Store for iPhone, iPad and Mac. No subscription needed. Once it is installed, tap this link again and the show is yours. Already have it? Open in Parasocial.
About
On Translating Aging, we talk with the worldwide community of researchers, entrepreneurs, and investors who are moving longevity science from the lab to the clinic. We bring you a commanding view of the entire field, in the words of the people and companies who are moving it forward today. The podcast is sponsored by BioAge labs, a clinical-stage biotechnology company developing therapies to extend human healthspan by targeting the molecular causes of aging.
Also on
Recent episodes
- A Promise Kept — Phase 1 Data for a 7-KC-Clearing Drug (Oki O'Connor, Cyclarity Tx)
- Beyond senolytics: senoadaptive drugs & clinical data on GPX4 modulation (Dr. Marco Quarta, Rubedo)
- Investing in the Future of Longevity (Sergey Jakimov, Managing Partner, LongeVC)
- Molecules to medicine: The translational landscape of aging interventions (Panel discussion at BAAM 2025)
- Partial epigenetic reprogramming: the "holy grail" for aging therapeutics (Michael Ringel, Life Biosciences)
- Cell Reset Therapeutics to Extend Healthspan and Lifespan (Janine Sengstack, Junevity)
- Building the Infrastructure for Longevity Medicine: ARPA-H's PROSPR Program (Dr. Andrew Brack, Program Manager)
- Decoding Stem Cell Rejuvenation Factors (Markus Gstöttner, CEO of Clock.bio)
- Eliminating Pathogenic Cells to Treat Disease (Adam Freund & Remi Laberge, Arda Therapeutics)
- Precision Epigenetic Medicines to Extend Healthspan (Alex Aravanis, Moonwalk Biosciences)